CO6382188A2 - Anticuerpos monoclonales que se unen al hgm-csf y composiciones medicas que los comprenden - Google Patents

Anticuerpos monoclonales que se unen al hgm-csf y composiciones medicas que los comprenden

Info

Publication number
CO6382188A2
CO6382188A2 CO10070935A CO10070935A CO6382188A2 CO 6382188 A2 CO6382188 A2 CO 6382188A2 CO 10070935 A CO10070935 A CO 10070935A CO 10070935 A CO10070935 A CO 10070935A CO 6382188 A2 CO6382188 A2 CO 6382188A2
Authority
CO
Colombia
Prior art keywords
hgm
csf
monoclonal antibodies
join
understand
Prior art date
Application number
CO10070935A
Other languages
English (en)
Inventor
Kenzo Takada
Kantou Nakajima
Barbara Kistler
John Park
Original Assignee
Evec Inc
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evec Inc, Boehringer Ingelheim Int filed Critical Evec Inc
Publication of CO6382188A2 publication Critical patent/CO6382188A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen aquí anticuerpos monoclonales anti- hGM-CSF y fragmentos de unión a antígeno de tales anticuerpos, con capacidad de neutralización mejorada para la actividad de hGM-CSF. También se proporcionan composiciones farmacéuticas que comprenden tal un anticuerpo o fragmento de unión a antígeno.La presente invención es útil para el tratamiento de varias entermedades que se asocian con expresión aberrante de hGM-CSF.
CO10070935A 2007-11-13 2010-06-11 Anticuerpos monoclonales que se unen al hgm-csf y composiciones medicas que los comprenden CO6382188A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007294945 2007-11-13
JP2008052471 2008-02-14

Publications (1)

Publication Number Publication Date
CO6382188A2 true CO6382188A2 (es) 2012-02-15

Family

ID=40329216

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10070935A CO6382188A2 (es) 2007-11-13 2010-06-11 Anticuerpos monoclonales que se unen al hgm-csf y composiciones medicas que los comprenden

Country Status (32)

Country Link
US (2) US8679502B2 (es)
EP (3) EP2535353A1 (es)
KR (1) KR20100102108A (es)
CN (2) CN101970489B (es)
AR (1) AR069290A1 (es)
AU (1) AU2008321429A1 (es)
BR (1) BRPI0820530A2 (es)
CA (1) CA2705539A1 (es)
CL (1) CL2008003361A1 (es)
CO (1) CO6382188A2 (es)
DK (1) DK2215119T3 (es)
EC (1) ECSP10010251A (es)
ES (1) ES2401536T3 (es)
HK (1) HK1146729A1 (es)
HR (1) HRP20130204T1 (es)
IL (1) IL205576A0 (es)
MA (1) MA31899B1 (es)
ME (1) ME01005B (es)
MX (1) MX2010005291A (es)
NZ (2) NZ586027A (es)
PE (1) PE20091420A1 (es)
PL (1) PL2215119T3 (es)
PT (1) PT2215119E (es)
RS (1) RS52713B (es)
RU (2) RU2517596C2 (es)
SG (1) SG176499A1 (es)
SI (1) SI2215119T1 (es)
TN (1) TN2010000210A1 (es)
TW (2) TW201206955A (es)
UY (1) UY31466A1 (es)
WO (1) WO2009064399A1 (es)
ZA (1) ZA201003467B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
WO2008141391A1 (en) * 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies
US20100297135A1 (en) * 2007-11-12 2010-11-25 Crc For Asthma And Airways Ltd. Epitope for neutralizing antibodies
BRPI0820530A2 (pt) 2007-11-13 2015-06-16 Boehringer Ingelheim Int Anticorpos monoclonais que se ligam ao hgm-csf e composições medicinais compreendendo os mesmos
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
BRPI0918103A2 (pt) 2008-12-22 2016-07-05 Univ Melbourne "método para o tratamento da dor em um indivíduo"
CA2746827C (en) 2008-12-22 2018-01-23 The University Of Melbourne Osteoarthritis treatment
CN102971005A (zh) 2010-06-24 2013-03-13 贝林格尔.英格海姆国际有限公司 糖尿病治疗
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
BR112013033944A2 (pt) 2011-07-06 2017-12-19 Morphosys Ag combinação sinérgica
IN2015KN00657A (es) 2012-09-20 2015-07-17 Morphosys Ag
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9833410B2 (en) * 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
US20160024200A1 (en) * 2013-03-14 2016-01-28 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
CA2922251C (en) 2013-08-30 2023-10-17 Takeda Gmbh Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
EP3139960B1 (en) 2014-05-07 2024-01-17 Takeda Pharmaceutical Company Limited Liquid formulation comprising gm-csf neutralizing compound
KR101953706B1 (ko) * 2016-09-19 2019-03-05 아이-맵 항-gm-csf 항체 및 이것의 사용
EP3645049A4 (en) 2017-06-25 2021-06-30 Systimmune, Inc. MULTISPECIFIC ANTIBODIES AND ASSOCIATED PREPARATION AND USE PROCESSES
US20220135687A1 (en) * 2017-12-28 2022-05-05 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against pd-l1
EP3623382A1 (en) * 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8624899D0 (en) * 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
WO1989011864A1 (en) * 1988-05-31 1989-12-14 Schering Biotech Corporation Method of treating myeloid leukemias
JPH04503815A (ja) 1989-07-14 1992-07-09 シェリング・コーポレーション カルボキシル末端から誘導されたｇｍ―ｃｓｆのアンタゴニスト
GB8925590D0 (en) * 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
AU8910891A (en) 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
CA2060741A1 (en) 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
WO1997014719A1 (en) * 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
US5662138A (en) * 1996-06-12 1997-09-02 Wang; Wen-Hsing Drop head structure
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
KR101287395B1 (ko) * 2000-06-16 2014-11-04 휴먼 게놈 사이언시즈, 인코포레이티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US7229784B2 (en) * 2000-09-19 2007-06-12 Microbia, Inc. Modulation of secondary metabolite production by zinc binuclear cluster proteins
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003040341A2 (en) * 2001-11-07 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-hepatitis a virus antibodies
ATE509032T1 (de) * 2002-02-13 2011-05-15 Ludwig Inst For Cancer Res Ltd Chimerizierte gm-csf antikörper
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2005055946A2 (en) 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
UA89364C2 (en) 2003-12-03 2010-01-25 Биодженерикс Аг Granulocyte colony stimulating factor peptide conjugate (g-csf)
DE602004021773D1 (de) 2004-05-05 2009-08-13 Micromet Ag Herstellung eines einkettigen fv Antikörperfragments
WO2006011353A1 (ja) 2004-07-30 2006-02-02 Thk Co., Ltd. ねじ溝加工方法
EA017420B9 (ru) * 2005-04-18 2013-03-29 Микромет Аг Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
DK1888643T3 (en) * 2005-05-18 2015-01-05 Morphosys Ag Anti-GM-CSF antibodies as well as their uses
JP4736037B2 (ja) * 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
HUE032584T2 (en) * 2006-02-08 2017-09-28 Morphotek Inc Antigen GM-CSF peptides and GM-CSF antibodies
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
EP2402013A1 (en) 2006-11-21 2012-01-04 Kalobios Pharmaceuticals, Inc. Methods of Treating Chronic Inflammatory Diseases using a GM-CSF Antagonist
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
BRPI0820530A2 (pt) 2007-11-13 2015-06-16 Boehringer Ingelheim Int Anticorpos monoclonais que se ligam ao hgm-csf e composições medicinais compreendendo os mesmos

Also Published As

Publication number Publication date
RU2010123693A (ru) 2011-12-20
PT2215119E (pt) 2013-02-11
SG176499A1 (en) 2011-12-29
CL2008003361A1 (es) 2010-02-05
RS52713B (en) 2013-08-30
HRP20130204T1 (hr) 2013-04-30
PL2215119T3 (pl) 2013-06-28
CN104072613A (zh) 2014-10-01
TN2010000210A1 (en) 2011-11-11
US20110182905A1 (en) 2011-07-28
CA2705539A1 (en) 2009-05-22
US8679502B2 (en) 2014-03-25
EP2535353A8 (en) 2013-04-03
DK2215119T3 (da) 2013-02-04
EP2215119A1 (en) 2010-08-11
HK1146729A1 (en) 2011-07-08
MA31899B1 (fr) 2010-12-01
TW201206955A (en) 2012-02-16
BRPI0820530A2 (pt) 2015-06-16
CN101970489A (zh) 2011-02-09
MX2010005291A (es) 2010-11-12
NZ586027A (en) 2012-01-12
TW200927760A (en) 2009-07-01
US20140205611A1 (en) 2014-07-24
SI2215119T1 (sl) 2013-04-30
UY31466A1 (es) 2009-07-17
EP2559706A1 (en) 2013-02-20
RU2517596C2 (ru) 2014-05-27
KR20100102108A (ko) 2010-09-20
WO2009064399A1 (en) 2009-05-22
TWI434854B (zh) 2014-04-21
PE20091420A1 (es) 2009-10-17
ES2401536T3 (es) 2013-04-22
NZ597023A (en) 2013-07-26
EP2535353A1 (en) 2012-12-19
ECSP10010251A (es) 2010-08-31
ZA201003467B (en) 2012-01-25
ME01005B (me) 2012-10-20
AU2008321429A1 (en) 2009-05-22
CN101970489B (zh) 2014-06-11
AR069290A1 (es) 2010-01-13
EP2215119B1 (en) 2012-12-26
IL205576A0 (en) 2010-11-30
RU2013141223A (ru) 2015-03-20

Similar Documents

Publication Publication Date Title
CO6382188A2 (es) Anticuerpos monoclonales que se unen al hgm-csf y composiciones medicas que los comprenden
CO6290643A2 (es) Derivados ciclopropilamina
CY1122490T1 (el) Αντισωματα κατα του ανθρωπινου cd38
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
BR112018074155A2 (pt) anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
CU20170169A7 (es) Anticuerpos de factor xi
IL212633A (en) A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs
CR20130624A (es) Proteínas de unión a antígeno
CR20120577A (es) Anticuerpos hacia gdf8 humano
BR112013004056B8 (pt) Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende
UA115122C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
MX348581B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
ECSP088778A (es) Formulacion de un anticuerpo monoclonal humano anti-igf-1r
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MX348579B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
AR119346A1 (es) Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados
CY1123926T1 (el) Αντισωματα κατα της τρανσγλουταμινασης 2
AR093620A1 (es) Anticuerpos bmp-6
AR083937A1 (es) Proteinas de union a antigenos
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos

Legal Events

Date Code Title Description
FG Application granted